Wang Xie NaNa Hu LeJie Cao
10.3389/fimmu.2021.790051
Front Immunol
2021 Dec 9;12:790051.
atezolizumab immune checkpoint inhibitor immune thrombocytopenia immune-related adverse event (irae) programmed cell death 1 inhibitor
CC BY
https://pubmed.ncbi.nlm.nih.gov/34956221/
Adenocarcinoma of Lung / drug therapy Antibodies, Monoclonal, Humanized / adverse effects Blood Platelets / drug effects Immune Checkpoint Inhibitors / adverse effects Lung Neoplasms / drug therapy Purpura, Thrombocytopenic, Idiopathic / chemically induced
Adenocarcinoma of Lung / drug therapy Antibodies, Monoclonal, Humanized / adverse effects Blood Platelets / drug effects Immune Checkpoint Inhibitors / adverse effects Lung Neoplasms / drug therapy Purpura, Thrombocytopenic, Idiopathic / chemically induced Case Reports Research Support, Non-U.S. Gov't Review Adenocarcinoma of Lung / immunology Adenocarcinoma of Lung / pathology Aged Blood Platelets / immunology Humans Lung Neoplasms / immunology Lung Neoplasms / pathology Male Purpura, Thrombocytopenic, Idiopathic / diagnosis Purpura, Thrombocytopenic, Idiopathic / immunology Purpura, Thrombocytopenic, Idiopathic / therapy Risk Factors Treatment Outcome Antibodies, Monoclonal, Humanized Immune Checkpoint Inhibitors atezolizumab
PMC8695900
34956221
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer: Case Report and Literature Review
2021